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ZD2767 is the latest antibody directed enzyme prodrug therapy
(ADEPT) system to be developed and is currently undergoing
Phase 1 clinical evaluation in patients with carcinoembryonic
antigen (CEA)-expressing tumours. The ZD2767 ADEPT system
utilizes the A5B7 F(ab´)2-carboxypeptidase G2 (CPG2) conjugate
(ZD2767C) which is targeted at CEA-expressing tumours. The
enzyme specifically activates a di-iodophenol mustard gluta-
mate prodrug (4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl
L-glutamic acid, ZD2767P, Figure 1A) to the potent di-iodo-
phenol mustard (4-[N,N-bis(2-iodoethyl)amino]phenol, ZD2767D,
Figure 1B), via the cleavage of the carbamate bond releasing the
glutamate moiety (Springer et al, 1995; Blakey et al, 1996).
Previously, it has been shown that ZD2767P + CPG2 is a potent
cytotoxic treatment, which produces concentration-dependent
DNA–DNA inter-strand cross-links as the primary cytotoxic
lesion (Monks et al, unpublished observations). Maximum levels
of cross-links are formed within 10 min of drug exposure, and
levels of cross-links determine, in part, the cytotoxicity of
ZD2767P + CPG2. However, the extracellular ZD2767P + CPG2
concentration required to induce similar levels of DNA cross-
linking and cytotoxicity varied 10-fold in a panel of colorectal and
non-small-cell lung cancer cell-lines, suggesting that cellular
factors prior to DNA interaction determine the levels of cross-
linking achieved for a given extracellular concentration.
Numerous cellular mechanisms have been identified which can
determine the activity of nitrogen mustards. These include drug
influx and efflux, decreased drug activation, cellular detoxification
(chemical and enzymatic), repair of drug-induced lesions and a
reduced ability to initiate apoptosis (Hayes and Wolf, 1990; Hall
and Tilby, 1992). Of the potential determinants of ZD2767 cyto-
toxicity, reduced influx, enhanced efflux or impaired activation are
unlikely to be important, because ZD2767D is a low molecular
weight uncharged direct-acting alkylating agent. As indicated
above, levels of ZD2767-induced DNA–DNA cross-linking deter-
mine, in part, cytotoxicity. Therefore, variation in the cellular
detoxification of ZD2767D prior to reaction with DNA, specifi-
cally by reaction with glutathione (GSH), may explain differences
between cell-lines in their sensitivity to ZD2767P + CPG2.
The aim of the studies reported here were to investigate the rela-
tionship between basal GSH concentration and the sensitivity of
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Figure 1 Structures of the compounds investigated. (A) 4-[N,N-bis(2-
iodoethyl)amino]phenoxycarbonyl L-glutamic acid prodrug (ZD2767P),
(B) 4-[N,N-bis(2-iodoethyl)amino]phenol drug (ZD2767D), (C) chlorambucil
and (D) melphalan.colorectal cell-lines to ZD2767P + CPG2 and, for comparison,
chlorambucil (Figure 1C). Buthionine sulfoximine (BSO)-medi-
ated depletion of GSH was also investigated to establish the extent
of the potentiation of ZD2767P + CPG2 activity that could be
achieved compared to the classical nitrogen mustards chloram-
bucil and melphalan (Figure 1D).
MATERIALS AND METHODS
The prodrug ZD2767P was synthesized as described previously
by Springer et al (1995). Chlorambucil and melphalan were
purchased from Sigma (Poole, Dorset, UK). CPG2 was provided
by CAMR (Salisbury, Wiltshire, UK). The colorectal tumour cell-
lines HT29, LoVo, LS174T, HCT116, HCT15 and SW620 were
obtained from the European Collection of Animal Cell Cultures
(ECACC, Wiltshire, UK). All cell-lines were maintained in RPMI
1640 (complete) medium containing 2 mM L-glutamine (Gibco-
BRL Life Technologies Ltd, Paisley, UK), supplemented with
10% (v/v) foetal calf serum (Globepharm Ltd, Esher, Surrey, UK),
and incubated at 37°C in 5% CO2. All cell-lines were routinely
tested for mycoplasma using the method of Chen (1977). All other
reagents were supplied by Sigma Chemical Co (Poole, Dorset,
UK), unless stated otherwise.
Growth inhibition studies
The tumour cell-lines were incubated with ZD2767P + CPG2
(0.1 unit well–1), chlorambucil or melphalan at the indicated
concentrations, in 96-well microtiter plates (1 ´ 103–1 ´ 104 cells
well–1) for 1 h. The medium was subsequently removed and the
cells incubated in 200 ml of drug-free medium for a further 96 h.
Cell growth was determined using the sulphorhodamine B (SRB)
dye assay as previously described by Skehan et al (1990).
Glutathione determination
Intracellular GSH levels were determined by HPLC using
adaptations of previous methods (Cotgreave and Moldeus, 1986;
Hogarth et al; 1999). Cell volumes were determined using a
Coulter counter (Model Z1, Coulter Electronics, UK).
RESULTS
GSH concentrations in each of the cell-lines were determined in
duplicate in each experiment and expressed as the absolute mM
cellular GSH concentration. GSH concentrations varied between
the cell-lines (Table 1) with HT29 and LS174T cells having the
highest basal GSH concentrations (5.5 and 4.6 mM, respectively),
and HCT15 cells the lowest (0.9 mM).
To investigate the possible role of GSH as a determinant of the
in vitro sensitivity of colorectal cell-lines to ZD2767P + CPG2, the
levels of GSH were compared with the IC50 data generated for
ZD2767P + CPG2 and chlorambucil (Table 2). No clear relation-
ship was identified between GSH concentration and sensitivity to
either ZD2767P + CPG2 or chlorambucil (linear regression
analysis,  r2 < 0.05, P > 0.67).
To determine the effect of GSH depletion in individual cell-lines
on sensitivity to ZD2767P + CPG2, HT29, LoVo and LS174T
cells were treated with 10 mM BSO for 24 h, a non-toxic concen-
tration which reduced the levels of total intracellular GSH by
73–83% (Table 3). BSO pre-treatment was shown to sensitise all 3
cell lines to ZD2767P + CPG2 (Table 3). However, the effect was
not statistically significant in either the HT29 or LS174T cell-
lines, with 10 mM BSO producing only a 2.3 and 1.9-fold
reduction in IC50 values, respectively.
To assess whether the level of BSO-mediated potentiation seen
with ZD2767P + CPG2 was comparable to that achievable with
classical nitrogen mustards, HT29 cells were exposed to 10 mM
BSO for 24 h prior to a 1 h exposure to ZD2767P + CPG2, chlo-
rambucil or melphalan. GSH depletion by 10 mM BSO was shown
to increase the sensitivity of HT29 cells to all three alkylating
agent treatments by 2.2–3-fold (Table 4). Although an increase in
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Table 1 Basal GSH levels in human colorectal tumour cell-lines
Cell-line Cell volume Intracellular GSH
(picolitres) concentration (mM)
HT29 2.24 ± 0.08 5.5 ± 0.89
LS174T 1.32 ± 0.04 4.6 ± 0.20
HCT116 1.52 ± 0.13 2.8 ± 0.66
LoVo 1.46 ± 0.12 2.2 ± 0.34
SW620 1.32 ± 0.04 2.2 ± 0.38
HCT15 1.39 ± 0.11 0.9 ± 0.07
Results were generated by gradient HPLC analysis as described in the
methods. Values are the mean ± S.D of ³ 3 experiments
Table 2 IC50 values for growth inhibition in colorectal cell-lines treated with
ZD2767P + CPG2 or chlorambucil
Cell-line ZD2767P + CPG2 Chlorambucil
IC50 (mM) IC50 (mM)
HCT116 1.1 ± 0.47 277 ± 106
HT29 0.82 ± 0.62 201 ± 61
HCT15 0.78 ± 0.07 76 ± 11
LoVo 0.41 ± 0.14 79 ± 5
SW620 0.25 ± 0.01 66 ± 5
LS174T 0.04 ± 0.03 26 ± 4
Cells were exposed to ZD2767P + 1 unit ml–1 CPG2 or chlorambucil for 1 h,
followed by 96 h incubation in drug-free medium. Growth inhibition was
assessed using the SRB assay. Values are the mean ± S.D of ³ 3
experiments
Table 3 Depletion of GSH and the potentiation of ZD2767P + CPG2-
induced growth inhibition in colorectal tumour cell-lines following a 24 h
exposure to 10 mM BSO
Cell-line BSO GSH ZD2767P + CPG2 Reduction in
concentration content IC50 (mM) IC50
(mM) (% Control) (fold)
HT29 0 0.73 ± 0.2
10 17 0.32 ± 0.04 (ns) 2.3
LoVo 0 0.38 ± 0.08
10 27 0.19 ± 0.03 (P < 0.05) 2
LS174T 0 0.021 ± 0.003
10 25 0.011 ± 0.008 (ns) 1.9
GSH levels were determined using gradient HPLC analysis following 24 h
exposure to BSO, and growth inhibition following 1 h exposure to ZD2767P +
1 unit ml–1 CPG2 using the SRB dye assay after 96 h drug-free incubation.
The data given are the mean ± S.D for three separate experiments.
Statistical analysis was performed using the two-tailed unpaired Welch’s
t-testsensitivity was observed, statistical analyses (paired students
t-test) showed that the effect was only significant at the 5% level in
the case of melphalan (P = 0.02), but not for ZD2767P + CPG2 or
chlorambucil (P = 0.13 and 0.07, respectively).
DISCUSSION
The studies reported in this paper were performed to determine the
role of intracellular GSH as a determinant of the sensitivity of
colorectal cell-lines to ZD2767P + CPG2. Analysis of basal GSH
levels identified differences between the colorectal tumour cell-
lines, concentrations ranging from 5.5 mM in HT29 cells to as low
as 0.9 mM in HCT15 cells. The lack of any clear relationship
between sensitivity to ZD2767P + CPG2 or chlorambucil and
basal GSH levels suggests that other cellular factors are more
important in determining inherent sensitivity in the cell-lines
studied. GSH concentration has previously been shown to corre-
late with nitrogen mustard sensitivity in resistant tumour cell-lines,
which suggests that acquired resistance but not inherent sensitivity
to nitrogen mustards can be related, in part, to intracellular GSH
content (Alaoui-Jamali et al, 1992; Friedman et al, 1994).
To investigate further the potential role of GSH as a determinant
of the sensitivity of colorectal tumour cells to ZD2767P + CPG2
and chlorambucil, buthionine sulfoximine (BSO) was used to
inhibit GSH synthesis and deplete GSH-levels prior to drug treat-
ment. Although GSH depletion sensitized all three cell-lines to
ZD2767P + CPG2, the effects were modest and, with the excep-
tion of the LoVo cell-line, not significant at the 5% level.
To compare the effects of GSH depletion on the potentiation of
ZD2767P + CPG2, chlorambucil or melphalan activity, HT29
colorectal tumour cells were pre-treated with 10 mM BSO. This
non-toxic BSO concentration produced an 83% depletion of GSH
levels but only a modest potentiation of the activity of the three
agents, (only significant in the case of melphalan).
There are a number of factors which could explain the lack of
any marked (i.e. > 3-fold) potentiation following BSO-mediated
depletion of GSH, both in this study and in similar studies with
nitrogen mustards reported previously. A major consideration is
that despite achieving > 73% depletion of intracellular GSH,
residual GSH concentrations are still in the mM range, i.e. far in
excess of the extracellular drug concentrations used in these inves-
tigations. Furthermore, GSH compartmentalization, specifically in
the nucleus, may explain the lack of potentiation seen following
BSO-mediated GSH depletion (Smith et al, 1996).
In conclusion, these studies have demonstrated that cellular
sensitivity to the ADEPT components ZD2767P + CPG2 is not
related to intracellular GSH levels. BSO-mediated GSH depletion
by as much as 83% resulted in only a modest potentiation of
ZD2767P + CPG2 activity (2–3 fold), a magnitude similar to that
observed with the classical nitrogen mustards chlorambucil and
melphalan. On the basis of these data, tumour GSH levels are
unlikely to be a determinant of the clinical activity of ZD2767
ADEPT, and combination studies involving BSO are not indicated.
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Table 4 IC50 values for the growth inhibition of HT29 colorectal tumour cells
after 1 h exposure to ZD2767P + CPG2, chlorambucil or melphalan following
24 h exposure with 10 mM BSO
Drug IC50 (mM) IC50 (mM) Reduction in
+ 10 mM BSO IC50 (fold)
ZD2767P + CPG2 0.47 ± 0.31 0.16 ± 0.12 3 ± 0.9
Chlorambucil 270 ± 120 120 ± 54 2.2 ± 0.4
Melphalan 63 ± 26 29 ± 19 2.5 ± 0.7
Growth inhibition was assessed using the SRB dye assay after 96 h
incubation in drug-free medium. The data are the mean ± S.D. of three
separate experiments. Statistical analysis was performed using the two-tailed
paired Students t-test